Literature DB >> 2583409

Activation of the complement system in primary sclerosing cholangitis.

G Senaldi1, P T Donaldson, S Magrin, J M Farrant, G J Alexander, D Vergani, R Williams.   

Abstract

Recent evidence, including the presence of circulating immune complexes, suggests that abnormalities of humoral immunity may be important in the pathogenesis of primary sclerosing cholangitis. The aim of the present study was to determine whether activation of the complement system is present in patients with this disease, as this would be supportive evidence of a role for circulating immune complexes in primary sclerosing cholangitis. Plasma complement fragments C3d and C4d, and serum C3 and C4, their respective parent molecules, have been assayed. Both C3d and C4d were elevated in patients with primary sclerosing cholangitis compared with patients with extrahepatic obstructive cholestasis and normal controls (p less than 0.01 in all instances). C3 was elevated in both patient groups, in whom it was similar, compared with normal controls (p less than 0.001 in both cases), whereas C4 was similar in all groups. Elevated levels of circulating immune complexes were identified in 21 of 24 (88%) patients with primary sclerosing cholangitis, but in none of the normal controls. These findings support the hypothesis that in primary sclerosing cholangitis circulating immune complexes are associated with activation of complement via the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583409     DOI: 10.1016/0016-5085(89)90386-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Immunological abnormalities and hepatotropic viral infections.

Authors:  I G McFarlane
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

3.  Review.

Authors:  Christopher B O'Brien
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

Review 4.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 5.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 6.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

7.  Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution.

Authors:  Mohannad Dugum; Medhat Askar; Rish K Pai; Lisa Yerian; Ana Bennett; James McMahon; Hao Xie; Bijan Eghtesad; Ibrahim Hanouneh; Xiuli Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

8.  Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.

Authors:  D H Van Thiel; P Carroll; K Abu-Elmagd; H Rodriguez-Rilo; W Irish; J McMichael; T E Starzl
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

9.  Small duct cholangitis induced by N-formyl L-methionine L-leucine L-tyrosine in rats.

Authors:  S Yamada; M Ishii; L S Liang; T Yamamoto; T Toyota
Journal:  J Gastroenterol       Date:  1994-10       Impact factor: 7.527

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.